Barclays PLC Analysts Give Illumina Inc. (ILMN) a $142.00 Price Target
Illumina Inc. (NASDAQ:ILMN) received a $142.00 price objective from investment analysts at Barclays PLC in a research note issued to investors on Tuesday. The firm currently has a an “equal weight” rating on the life sciences company’s stock. Barclays PLC’s target price suggests a potential upside of 4.27% from the stock’s previous close.
A number of other analysts have also issued reports on ILMN. Zacks Investment Research raised Illumina from a “sell” rating to a “hold” rating in a research note on Monday, July 4th. Cantor Fitzgerald reaffirmed a “hold” rating on shares of Illumina in a research note on Wednesday, June 29th. Mizuho lifted their price target on Illumina from $138.00 to $148.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 27th. Vetr lowered Illumina from a “buy” rating to a “sell” rating and set a $142.96 price target on the stock. in a research note on Tuesday, July 26th. Finally, Janney Montgomery Scott lowered Illumina from a “neutral” rating to a “sell” rating and lowered their price target for the stock from $155.00 to $125.00 in a research note on Tuesday. Two investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $158.34.
Illumina (NASDAQ:ILMN) traded down 2.02% during mid-day trading on Tuesday, reaching $136.18. The company’s stock had a trading volume of 2,882,381 shares. Illumina has a 12-month low of $127.10 and a 12-month high of $196.47. The firm’s 50 day moving average price is $174.01 and its 200 day moving average price is $156.43. The stock has a market cap of $19.96 billion, a price-to-earnings ratio of 46.64 and a beta of 0.47.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, July 26th. The life sciences company reported $0.86 EPS for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.13. The business earned $600 million during the quarter, compared to analysts’ expectations of $31.91 million. Illumina had a return on equity of 23.69% and a net margin of 18.73%. The business’s revenue was up 11.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.80 earnings per share. On average, equities analysts predict that Illumina will post $3.53 earnings per share for the current year.
In related news, Director Roy A. Whitfield sold 4,000 shares of the company’s stock in a transaction dated Friday, August 12th. The stock was sold at an average price of $167.22, for a total value of $668,880.00. Following the completion of the sale, the director now directly owns 6,853 shares of the company’s stock, valued at approximately $1,145,958.66. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director A Blaine Bowman sold 5,000 shares of the company’s stock in a transaction dated Thursday, July 14th. The shares were sold at an average price of $147.14, for a total value of $735,700.00. Following the completion of the sale, the director now directly owns 20,704 shares of the company’s stock, valued at $3,046,386.56. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of the company. Physicians Financial Services Inc. boosted its stake in Illumina by 2,121.2% in the second quarter. Physicians Financial Services Inc. now owns 733 shares of the life sciences company’s stock worth $103,000 after buying an additional 700 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in Illumina by 25.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 789 shares of the life sciences company’s stock worth $110,000 after buying an additional 158 shares during the last quarter. Fuller & Thaler Asset Management Inc. bought a new stake in Illumina during the second quarter worth $112,000. Ropes Wealth Advisors LLC boosted its stake in Illumina by 72.6% in the second quarter. Ropes Wealth Advisors LLC now owns 863 shares of the life sciences company’s stock worth $121,000 after buying an additional 363 shares during the last quarter. Finally, Checchi Capital Advisers LLC boosted its stake in Illumina by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 958 shares of the life sciences company’s stock worth $134,000 after buying an additional 22 shares during the last quarter. 95.22% of the stock is owned by institutional investors.
Illumina Company Profile
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.